The new prognosis of systemic lupus erythematosus: Treatment-free remission and decreased mortality and morbidity

Israel Medical Association Journal

Volumn 2, Issue 5, 2000, Pages 382-387

  Drenkard, C ^a   Alarcon Segovia, D ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiphospholipid syndrome; Disease remission; Mortality; Prognosis; Systemic lupus erythematosus

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DEMOGRAPHY; GENDER; HEALTH STATUS; KIDNEY DISEASE; MORBIDITY; MORTALITY; ONSET AGE; PROGNOSIS; QUALITY OF LIFE; RACE; REMISSION; REVIEW; SOCIAL ASPECT; SOCIOECONOMICS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

DISEASE-FREE SURVIVAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 0033838937     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Remission of systemic lupus erythematosus
2. Mortality studies in systemic lupus erythematosus. Results from a single center. III: Improved survival over 24 years
3. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992
4. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus
5. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population
6. Lupus erythematosus in the 1980s: A survey of 570 patients
7. Variables associated with decreased survival in systemic lupus erythematosus
8. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus
9. Mortality studies in systemic lupus erythematosus. Results from a single center. I: Causes of death
10. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients
11. Survival in patients with systemic lupus erythematosus in India
12. Survival of Chilean patients with systemic lupus erythematosus
13. Differences in clinical and immunological findings of systemic lupus erythematosus related to age
14. Systemic lupus erythematosus in the younger patient: Survival studies
15. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death
16. Strategies for reducing excess morbidity and mortality in blacks with systemic lupus erythematosus
17. A multicenter study of outcome in systemic lupus erythematosus. I: Entry variables as predictors of prognosis
18. Systemic lupus erythematosus in three ethnic groups. I: The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset
19. Systemic lupus erythematosus in males. A study of 107 Latin American patients
20. Kidney biopsy in systemic lupus erythematosus. II: Survival analysis according to biopsy results
21. Dilemmas in neuropsychiatric lupus
22. Vasculitis in systemic lupus erythematosus
23. Psychosocial correlates of morbidity in women with systemic lupus erythematosus
24. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus
25. Measures of disease activity, damage, and health status. The Hopkins Lupus Cohort Experience
26. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus
27. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices
28. Natural history of hypercholesterolemia in systemic lupus erythematosus
29. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with predinisone and short-term oral cyclophosphamide
30. Lupus nephritis
31. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls
32. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus
33. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus
34. Outcome measures to be used in clinical trials in systemic lupus erythematosus
35. Associates of health status in patients with systemic lupus erythematosus
36. Quality of life in systemic lupus erythematosus: A controlled study
37. The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus
38. Objective and subjective sleep disturbances in patients with systemic lupus erythematosus
39. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus
40. Serologically active clinically quiescent systemic lupus erythematosus. A discordance between clinical and serologic features